Recent News

• 09.16.2025 - Biomea Fusion Presents Data Demonstrating Enhanced Preclinical Activity of Icovamenib in Combination with Semaglutide in Type 2 Diabetes (T2D) Animal Model at the 61st EASD Annual Meeting and Provides Additional Corporate Update
• 09.16.2025 - Biomea Fusion Presents Data Demonstrating Enhanced Preclinical Activity of Icovamenib in Combination with Semaglutide in Type 2 Diabetes (T2D) Animal Model at the 61st EASD Annual Meeting and Provides Additional Corporate Update
• 08.28.2025 - Roger Song, M.D
• 08.28.2025 - Roger Song, M.D
• 08.05.2025 - Biomea Fusion Reports Second Quarter 2025 Financial Results and Corporate Highlights
• 08.05.2025 - Biomea Fusion Reports Second Quarter 2025 Financial Results and Corporate Highlights
• 07.24.2025 - Julianne Averill
• 07.24.2025 - Julianne Averill

Recent Filings

• 08.15.2025 - EFFECT Notice of Effectiveness
• 08.13.2025 - 4 Statement of changes in beneficial ownership of securities
• 08.13.2025 - CORRESP Correspondence
• 08.13.2025 - SCHEDULE 13G/A Statement of Beneficial Ownership by Certain Investors
• 08.13.2025 - 4 Statement of changes in beneficial ownership of securities
• 08.12.2025 - UPLOAD SEC-generated letter
• 08.11.2025 - SCHEDULE 13G Statement of Beneficial Ownership by Certain Investors
• 08.05.2025 - 8-K Current report
• 08.05.2025 - S-3 Registration statement under Securities Act of 1933
• 08.05.2025 - EX-99.1 EX-99.1